Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease.
OBJECTIVE
To evaluate the role of fluorine 18 deoxyglucose positron emission tomography (FDG PET) in the initial staging of ocular adnexal lymphoma (OAL).


METHODS
Retrospective nonrandomized case series.


METHODS
Eleven patients with OAL who underwent FDG PET at initial staging.


METHODS
Retrospective review of all the clinical and imaging records, including computed tomography (CT) and FDG PET.


METHODS
The ability of PET studies to detect OAL and distant disease was compared with CT.


RESULTS
Eleven patients with OAL who underwent FDG PET at initial staging were retrospectively reviewed having full access to their clinical and imaging data. Fluorine 18 deoxyglucose PET found distant disease in 5 of 6 lymphoma patients with systemic disease; 4 of these patients (66%) were upstaged, changing the clinical management. Orbital lesions were demonstrated in 3 of 11 patients, giving PET a sensitivity of 27% in the orbit and 83% systemically for detection of lymphoma.


CONCLUSIONS
The ability of FDG PET to find systemic extranodal lymphomatous sites not detected with conventional imaging provides valuable information in OAL patients, which may result in important changes in staging and management. The technique does have limitations in detecting OAL compared with conventional imaging, possibly owing to background physiologic activity in the extraocular muscles in the orbit and the small volume of some orbital deposits.
Valenzuela
Alejandra A
AA
Eyelid, Lacrimal and Orbital Clinic, Department of Ophthalmology, Division of Surgery, Royal Brisbane and Women's Hospital and The University of Queensland Medical School, Herston, Australia.
Allen
Christopher
C
Grimes
David
D
Wong
David
D
Sullivan
Timothy J
TJ
D000328:Adult; D000368:Aged; D003230:Conjunctival Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005134:Eye Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D005142:Eyelid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007766:Lacrimal Apparatus Diseases / Q000000981:diagnostic imaging* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009918:Orbital Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18